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        Urinary tract infection (UTI) and pyelone-
phritis, which are usually caused by uropatho-
genic   Escherichia coli   (UPEC), are common 
infectious diseases that constitute a notable risk 
factor for the development of renal insuffi   -
ciency in children, young adults and renal 
transplanted patients (  1  –  3  ). Toll-like recep-
tor (TLR) 4, which recognizes LPS, an ob-
ligate constituent of the outer membrane of 
all Gram-negative bacteria, plays a central 
role in initiating the antibacterial host re-
sponse: LPS-defective (  Lps  d    ) C3H/HeJ mice 
exhibiting a loss-of-function mutation in the 
  Tlr4   gene are unresponsive to LPS (  4  ) and 
fail to clear Gram-negative bacteria colonizing 
the lower urinary tract and kidneys (  5  ). Us-
ing an experimental mouse model of ascend-
ing pyelo  nephritis, we have shown that when 
UPECs invade the kidneys, they bind specifi  -
cally to the apical surface of collecting duct (CD) 
cells (  6  ) and induce a potent proinfl  ammatory 
response via distinct TLR4-dependent and 
-independent signaling pathways (  6, 7  ). These 
fi  ndings indicate that, like bladder epithelial 
cells (  8  ), epithelial cells from the collecting 
duct (which is the fi  rst tubule segment to 
encounter ascending bacteria), together with 
bone marrow  –  derived cells (  8, 9  ), play a key 
role in initiating an innate immune response in 
the kidney. 
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  Ascending urinary tract infection (UTI) and pyelonephritis caused by uropathogenic   Esch-
erichia coli   (UPEC) are very common infections that can cause severe kidney damage. 
Collecting duct cells, the site of hormonally regulated ion transport and water absorption 
controlled by vasopressin, are the preferential intrarenal site of bacterial adhesion and 
initiation of infl  ammatory response. We investigated the effect of the potent V2 receptor 
(V2R) agonist deamino-8-D-arginine vasopressin (dDAVP) on the activation of the innate 
immune response using established and primary cultured collecting duct cells and an ex-
perimental model of ascending UTI. dDAVP inhibited Toll-like receptor 4  –  mediated nuclear 
factor     B activation and chemokine secretion in a V2R-specifi  c manner. The dDAVP-
mediated suppression involved activation of protein phosphatase 2A and required an intact 
cystic fi  brosis transmembrane conductance regulator Cl    −    channel. In vivo infusion of dDAVP 
induced a marked fall in proinfl  ammatory mediators and neutrophil recruitment, and a 
dramatic rise in the renal bacterial burden in mice inoculated with UPECs. Conversely, 
administration of the V2R antagonist SR121463B to UPEC-infected mice stimulated both 
the local innate response and the antibacterial host defense. These fi  ndings evidenced a 
novel hormonal regulation of innate immune cellular activation and demonstrate that 
dDAVP is a potent modulator of microbial-induced infl  ammation in the kidney. 2838 ARGININE VASOPRESSIN LIMITS RENAL INFLAMMATION | Chassin et al.
      RESULTS   
    Renal collecting duct mpkCCD  cl4   cells express TLR4 
and are sensitive to LPS 
  The identifi  cation of collecting duct cells as a preferential 
adhesion site for UPECs in an in vivo model of ascending UTI 
(  6  ) led us to analyze the mechanisms of cell activation in a 
highly diff  erentiated collecting duct cell line, mpkCCD  cl4  , 
derived from collecting ducts microdissected from the kidney 
of a transgenic SVPK-Tag mouse harboring the large T anti-
gen under the control of a truncated pyruvate kinase pro-
moter fused to an SV40 enhancer (  21  ). These cells formed 
confluent layers of epithelial-shaped cells, which in turn 
formed domes, a characteristic feature of layers of ion-trans-
porting epithelial cells (Fig. S1, available at http://www.jem
.org/cgi/content/full/jem.20071032/DC1). mpkCCD  cl4   cells 
expressed TLR4 as well as the accessory protein MD-2 and 
myeloid diff  erentiation factor 88 (MyD88; Fig. S1). They 
also expressed the mRNA of CD14 (Fig. S1), indicating that 
mpkCCD  cl4   cells might autonomously produce CD14, ren-
dering them independent of serum-derived soluble CD14. 
Western blotting using a specifi  c polyclonal rabbit anti-TLR4 
antiserum revealed a major protein band of the predicted size 
of      96 kD, which was not detected in the presence of an 
excess of the peptide used for immunization (  Fig. 1 A  ).   FACS 
analysis revealed predominantly intracellular staining of 
TLR4 (  Fig. 1 B  ), and immunofl  uorescence studies showed 
that TLR4 was mainly concentrated in the perinuclear region 
of the cytoplasm (  Fig. 1 C  , top), where it colocalized with 
the Golgi marker CTR433 (  Fig. 1 C  , bottom) (  24  ). These 
fi  ndings indicate that mpkCCD  cl4   cells express the LPS receptor 
complex TLR4  –  MD-2, which is mainly detected in the intra-
cellular compartment (i.e., in the Golgi apparatus), as previously 
reported in pulmonary epithelial cells (  25  ), endothelial cells 
(  26  ), and intestinal epithelial m-IC  cl2   cells (  27  ). 
  The recognition of LPS by TLR4 induces a cascade of 
events leading to activation of the nuclear transcription factor 
NF-    B signaling pathway and the subsequent production of 
chemokines and cytokines (  28  ). I    B-     undergoes ubiquitina-
tion and proteasome-mediated degradation, leading to the re-
lease and nuclear translocation of the NF-    B subunit p65/RelA 
(  29, 30  ). In mpkCCD  cl4   cells, LPS induced the nuclear trans-
location of NF-    B (  Fig. 1 D  , top). This nuclear redistribution 
was completely abolished after treatment with the specifi  c 
NF-    B inhibitor SN50. LPS also induced a dose-dependent 
increase in luciferase activity in cells transiently transfected 
with a NF-    B luciferase reporter gene construct (  Fig. 1 D  , 
bottom). 50 ng/ml TNF-    , used as positive control, similarly 
induced a signifi  cant increase in luciferase activity. Finally, 
LPS induced dose- and time-dependent stimulation of the 
secretion of the chemokine macrophage infl  ammatory protein 2 
(MIP-2;   Fig. 1 E  ), which was very signifi  cantly reduced in the 
presence of SN50 or polymyxin B, a competitive inhibitor of 
LPS (not depicted). These results indicate that mpkCCD  cl4   
cells provide a suitable in vitro cell system for analyzing regu-
latory mechanisms controlling TLR4-mediated cellular acti-
vation in renal collecting duct cells. 
  Collecting duct cells are a major site of the reabsorption 
of water and of NaCl from the primitive urine. These pro-
cesses are tightly regulated by hormones such as arginine 
vasopressin (AVP), a neuropeptide secreted into the systemic 
bloodstream by hypothalamic neurons, which binds to V2 
receptors (V2Rs) coupled to adenylyl cyclase and stimulates 
the cyclic AMP (cAMP)  –  protein kinase A (PKA) signaling 
pathway. This boosts the reabsorption of water by increasing 
the permeability of the apical membranes of the collecting 
duct principal cells (  10  ). AVP also stimulates the reabsorption 
of NaCl mediated by the epithelial sodium channel (ENaC) 
and activates the cAMP-sensitive cystic fi  brosis transmem-
brane conductance regulator (CFTR) Cl    −    conductance in 
cultured renal collecting duct cells (  11  –  13  ). Children with 
pyelonephritis exhibit increased levels of circulating AVP 
and develop polyuria with urinary concentrating defect, 
probably related to acute renal interstitial infl  ammation (  14  –  16  ). 
However, this does not exclude that vasopressin may pro-
duce unexpected biological eff  ects on renal cells indepen-
dently of its antidiuretic action. As a matter of fact, the 
mechanisms involved in the interplay between AVP and renal 
infl  ammatory responses caused by LPS or UPECs are still 
poorly understood. Previous studies have shown that in-
creased cell cAMP levels inhibit the TNF-      –  , LPS-, and 
IL-1      –  stimulated expression of adhesion molecules and sig-
naling molecules in a variety of cell types (  17  –  20  ). AVP, via its 
stimulatory action on cell cAMP content, might therefore 
inhibit the activation of target cells (i.e., collecting duct cells) 
after bacterial colonization of the kidney. However, the ef-
fects of AVP on proinfl  ammatory mediators and the upstream 
and downstream mechanisms of cAMP-mediated inhibition 
of cellular activation remain to be identifi  ed. The fact that 
UPECs preferentially adhere to AVP-sensitive collecting 
duct cells that are able to develop a potent infl  ammatory re-
sponse (  6  ) led us to hypothesize that AVP may infl  uence the 
innate immune response and aff  ect renal bacterial clearance. 
In the present study, we examine the eff  ects of 1-deamino-
8-D-AVP (dDAVP), a pure V2R agonist, on LPS recog-
nition in immortalized cortical collecting duct (CCD) 
mpkCCD  cl4   cells that have retained the main properties of 
the parent collecting duct cells (  11, 21  ) and their sensitivity 
to LPS (  22  ). We carefully analyze the underlying molecular 
process and show that dDAVP inhibits LPS-mediated cell 
activation through a dephosphorylation process, which is 
mainly mediated by the serine/threonine (Ser/Thr) protein 
phosphatase 2A (PP2A). Using CCD cells dissected from 
homozygous   cftr  m1unc     mice in which the   cftr   gene had been 
disrupted (  23  ) and their wild-type counterparts, we further 
demonstrated the important role played by CFTR in this 
process. Using an experimental model of ascending UTI (  4  ), 
we also provide in vivo demonstration of the relevance of the 
regulatory role of dDAVP in controlling renal infl  ammatory 
responses. Overall, our fi  ndings identify a novel AVP  –  CFTR  –
  Ser/Thr PP2A regulatory pathway involved in controlling 
the intrarenal innate immune response to pyelonephritis caused 
by UPEC. JEM VOL. 204, November 26, 2007 
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NF-    B subunit p65/RelA (phosphorylated p65) caused by 
LPS was no longer observed in the presence of dDAVP 
(  Fig. 2 B  ). Experiments using mpkCCD  cl4   cells confi  rmed 
that dDAVP induced a dose-dependent decrease of the LPS-
induced activation of NF-    B (  Fig. 2 C  ). Consistent with 
these fi  ndings, dDAVP caused dose-dependent inhibition of 
LPS-stimulated secretion of MIP-2 and TNF-     (  Fig. 2 D  ). 
A constant concentration of 10    −  8   M dDAVP also transac-
tivated NF-    B and stimulated the secretion of MIP-2, and 
TNF-     inhibited to the same extent at all concentrations of 
LPS tested (  Fig. 2, E and F  ), indicating that dDAVP does not 
bind to LPS in solution. To confi  rm that the inhibitory ac-
tion of dDAVP on LPS-mediated cell activation involved the 
binding of dDAVP to V2R, the production of MIP-2 was 
  dDAVP inhibits LPS-dependent NF-    B activation and 
secretion of MIP-2 and TNF-     in renal collecting duct 
mpkCCD  cl4   cells 
  Previous studies had demonstrated that AVP induces a rapid 
rise in cellular cAMP content and stimulates the reabsorp-
tion of NaCl and water by renal collecting duct cells (  17  –  20  ). 
We investigated whether dDAVP could aff  ect innate immune 
recognition of LPS in mpkCCD  cl4   epithelial cells. Incubating 
cells with 10    −  8   M dDAVP alone or with LPS for 6 h induced 
a signifi  cant rise in cAMP as compared with untreated cells 
(  Fig. 2 A  ).   LPS induced rapid time-dependent degradation 
of I    B-     and stimulated the phosphorylation of the NF-    B 
subunit p65/RelA (phosphorylated p65;   Fig. 2 B  ). The time-
dependent degradation of I    B-     and phosphorylation of the 
  Figure 1.     TLR4 expression in CCD mpkCCD  cl4   cells. (A) Western blot analysis of mpkCCD  cl4   cell lysates revealing a band of the predicted size 
(     96 kD; arrow) of TLR4, which was not detected in the presence of an excess of the peptide (+pep) used for immunization. (B) FACS analysis for TLR4 in 
nonpermeabilized and permeabilized cells. Nonbolded lines correspond to the isotype control. (C) Cellular immunolocalization of TLR4 performed with or 
without an excess of the peptide used for immunization (top), and colocalization of TLR4 with the Golgi apparatus marker CTR433 (bottom). Nuclei were 
counterstained with HOECHST 33258. Bars, 10     m. (D, top) Nuclear translocation of NF-    B p65/RelA in cells stimulated with 10 ng/ml LPS in the presence 
or absence of 18     M SN50 for 3 h. Bar, 10     m. (bottom) Effects of rising concentrations of LPS and 50 ng/ml TNF-     on  NF-   B activation in cells trans-
fected with the NF-    B luciferase reporter. (E) Effects of rising concentrations of LPS and time dependency on the secretion of MIP-2. Values are means   ±   SE 
from four to seven experiments. *, P   <   0.05 versus zero values.     2840 ARGININE VASOPRESSIN LIMITS RENAL INFLAMMATION | Chassin et al.
  Figure 2.     Inhibitory effect of dDAVP on LPS-mediated cellular activation. (A) Cell cAMP content in mpkCCD  cl4   cells incubated without or with 
10   − 8   M dDAVP, LPS, or dDAVP plus LPS for 6 h. (B) Time-dependent expression of I   B-    and     -actin and phosphorylated (p-p65) and total (p65) NF-   B 
p65/RelA in cells incubated with LPS (  −  dDAVP) or LPS plus dDAVP (+dDAVP). (C and D) Effects of rising concentrations of dDAVP on 10 ng/ml LPS  –
  induced cellular activation in mpkCCD  cl4   cells transfected with the NF-    B luciferase reporter (C), and on the secretion of MIP-2 and TNF-     (D). 
(E and F) Effects of 10   − 8   M dDAVP on 1  –  1,000 ng/ml LPS  –  induced cellular activation (E), and on the secretion of MIP-2 and TNF-     (F).  TNF-    was  used 
as control for the transactivation experiments. (G and H) Effects of SR121463B on the secretion of MIP-2 6 h after adding dDAVP and LPS. dDAVP and 
SR121463B had no effect on MIP-2 secretion stimulated by PMA. Results are expressed as means   ±   SE. *, P   <   0.05 versus LPS values.   JEM VOL. 204, November 26, 2007 
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In the absence of dDAVP, preincubating the cells with 10 nM 
calyculin A or okadaic acid had no eff  ect on LPS-stimulated 
secretion of MIP-2 or TNF-     (  Fig. 3 B  ). In sharp contrast, 
the two protein phosphatase inhibitors prevented the inhibitory 
eff  ect of dDAVP on the LPS-stimulated secretion of MIP-2 
and TNF-     (  Fig. 3 B  ). Although calyculin A and okadaic 
acid both inhibit PP1 and PP2A activities, the latter is a more 
selective inhibitor of PP2A at the 10-nM dose used (  36, 37  ). 
10 nM calyculin A and okadaic acid also impaired the inhibi-
tory eff  ect of 10    −  8   M dDAVP on the stimulated secretion of 
MIP-2 and TNF-     at all concentrations of LPS (1  –  1,000 ng/ml) 
tested (Fig. S3, available at http://www.jem.org/cgi/content/
full/jem.20071032/DC1). These fi  ndings strongly suggest that 
the increase in PP2A activity is directly responsible for the 
inhibitory eff  ect of dDAVP on the LPS-stimulated secretion 
of both MIP-2 and TNF-     by renal collecting duct cells. 
  Cl    −    channel inhibitors abolish the inhibitory activity 
of dDAVP on LPS-stimulated cytokine secretion 
  CFTR, a Cl    −    channel activated by cAMP-dependent PKA, 
can be dephosphorylated and inactivated by several Ser/Thr 
protein phosphatases (  38  –  41  ). CFTR mediates the electro-
genic apical secretion of Cl    −    stimulated by dDAVP in renal 
collecting duct cells (  12, 13  ). mpkCCD  cl4   cells express both 
ENaC and the CFTR Cl    −    channel (  Fig. 4 A  ).   Two recent 
studies have demonstrated that the CFTR Cl    −    channel is di-
rectly linked to PP2A (  42, 43  ). Inhibitors of PP2A were also 
shown to prolong the deactivation of cAMP-activated CFTR 
measured in mpkCCD  cl4   cells preincubated with increasing 
concentrations of SR121463B (see Materials and methods), 
a selective, nonpeptide V2R antagonist (  31  ). Stimulations 
were subsequently performed with 10 ng/ml LPS plus 10    −  8   M 
dDAVP. SR121463B produced concentration-dependent 
antagonism of the inhibitory action of dDAVP on LPS-in-
duced MIP-2 secretion: at 10    −  7   M, SR121463B completely 
antagonized the inhibitory action of dDAVP and restored the 
stimulatory activity of LPS (  Fig. 2 G  ). The V2R-mediated 
inhibitory action of dDAVP appeared to be specifi  c because 
neither dDAVP alone nor dDAVP plus SR121463B aff  ected 
PMA-induced cell stimulation (  Fig. 2 H  ). We then checked 
that dDAVP was acting specifi  cally on the TLR4-mediated 
cellular activation. Extinction of TLR4 mRNA expression 
by a specifi  c TLR4 small-interfering RNA (siRNA) com-
pletely inhibited the secretion of MIP-2 stimulated by LPS 
in mpkCCD  cl4   cells, whereas a negative control siRNA had 
no eff  ect (Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20071032/DC1). As a control, TLR4 ex-
tinction induced by the siRNA used had no eff  ect on PMA 
stimulation. Involvement of PKA in the inhibitory action of 
dDAVP on LPS activation was demonstrated by preincubat-
ing the cells for 30 min with 5   ×   10    −  5   M of the selective 
PKA inhibitor H89. H89 signifi  cantly reduced the inhibitory 
eff  ect of dDAVP on the LPS-mediated secretion of MIP-2 
(LPS + dDAVP = 429   ±   31 pg/ml; LPS + dDAVP + H89 = 
616   ±   11 pg/ml;   n   = 4; P   <   0.05). In contrast, preincubating 
cells with 10    −  6   M GF109203X, a protein kinase C inhibitor, 
did not aff  ect the inhibitory action of dDAVP on the LPS-
mediated secretion of MIP-2 (LPS + dDAVP = 495  ±   17 pg/ml; 
LPS + dDAVP + GF109203X = 503   ±   18 pg/ml;   n   = 4). 
Collectively, these fi  ndings indicate that dDAVP acts as a 
potent modulator of the TLR4-dependent activation of renal 
CCD cells. 
  The inhibitory effect of dDAVP on the LPS-induced 
secretion of MIP-2 and TNF-     is mediated by Ser/Thr 
protein phosphatases 
  dDAVP-induced down-regulation of LPS-mediated NF-    B 
activation suggests that this polypeptide hormone may alter 
the activation (i.e., phosphorylation) of signaling molecules. 
The phosphorylation of signaling molecules is regulated not 
only by protein kinases, but also by Ser/Thr protein phos-
phatases (  32  ). PP1 and PP2A, as well as a variety of protein 
kinases, are involved in the regulation of signaling pathways 
by a phosphorylation/dephosphorylation mechanism (  32  ). 
Interestingly, Ser/Thr PP2A is highly expressed in the distal 
nephron (  33  ) and is activated by dDAVP in mouse renal col-
lecting duct cells (  34  ). We therefore investigated whether 
dDAVP activated Ser/Thr protein phosphatase activity, and 
whether calyculin A and okadaic acid, two potent inhibitors of 
Ser/Thr PP1 and PP2A (  35  ), impaired the inhibitory eff  ect 
of dDAVP on LPS-mediated cell stimulation. Incubating 
mpkCCD  cl4   cells with 10    −  8   M dDAVP for 6 h signifi  cantly stim-
ulated PP2A activity ( Fig. 3 A ).   10 ng/ml LPS for 6 h also slightly 
increased the PP2A activity stimulated by dDAVP (  Fig. 3 A  ). 
  Figure 3.     Inhibitors of Ser/Thr protein phosphatases impair the 
inhibitory effect of dDAVP on the LPS-mediated cytokine secretion. 
(A) mpkCCD  cl4   cells were incubated with or without 10   − 8   M dDAVP, 10 ng/ml 
LPS, or dDAVP plus LPS for 6 h. Ser/Thr phosphatase activity was mea-
sured in cell homogenates using a synthetic phosphopeptide substrate. 
Error bars represent the mean phosphate release values   ±   SE from six 
separate experiments. (B) The secretion of MIP-2 and TNF-     was  mea-
sured in the cell supernatants after incubation with or without 10 ng/ml 
LPS or 10   − 8   M dDAVP plus LPS for 6 h in the presence or absence of 
10 nM calyculin A or okadaic acid. Values are means   ±   SE from four to seven 
separate experiments. *, P   <   0.05 versus basal and LPS values (A) or versus 
the other experimental conditions (B).     2842 ARGININE VASOPRESSIN LIMITS RENAL INFLAMMATION | Chassin et al.
cell activation. We therefore tested the eff  ects of various Cl    −    
channel inhibitors on mpkCCD  cl4   cells exposed to LPS alone 
or to LPS plus dDAVP for 6 h (  Fig. 4 B  ). 5-nitro-2(3phenyl-
propyl-amino)benzoate (NPPB) and glybenclamide (Gly) both 
inhibit mouse CFTR at high concentrations and also aff  ect 
other Cl    −    transporters, as well as K  +  -ATP  –  sensitive channels 
(  13, 44  –  46  ). The more potent and specifi  c CFTR inhibitor 
Cl    −    channels in colonic carcinoma Caco-2 cells (  42  ) and to 
increase CFTR channel activity in excised patches of airway 
and intestinal epithelium (  43  ). Although protein phosphatase 
inhibitors had no substantial eff  ects on dDAVP-stimulated 
Cl    −    fl uxes in mpkCCD  cl4   cells (unpublished data), we wanted 
to fi  nd out whether CFTR was involved in the observed 
PP2A-dependent inhibitory eff  ect of dDAVP on LPS-mediated 
  Figure 4.     Anion channel inhibitors prevent the inhibitory effect of dDAVP on LPS-mediated cytokine secretion. (A) mpkCCD  cl4   cells  expressed 
    -ENaC (564 bp) and CFTR (636 bp) mRNA. + represents reverse-transcribed RNA;   −   represents non  –  reverse-transcribed RNA. (B) MIP-2 and TNF-     secre-
tions were measured after incubating cells with or without 10 ng/ml LPS, 10   − 8   M dDAVP, or dDAVP plus LPS for 6 h in the presence or absence of 10   − 4   M 
NPPB, 10   − 4   M Gly, 10   − 7   M  CFTR inh  -172, or 10   − 5   M amiloride (Am). (C) Apical and basal secretion of MIP-2 and TNF-     measured on confl  uent cells grown on 
fi  lters and incubated with 10 ng/ml LPS, LPS plus 10   − 8   M dDAVP, or LPS plus dDAVP and 10   − 7   M  CFTR inh  -172. LPS was added either on the apical (Apical 
LPS) or basal (Basal LPS) side of the cell layers, dDAVP was added to the basal side of the cell layers, and CFTR  inh  -172 was added to the apical side of the 
cell layers. Values are means   ±   SE from fi  ve to eight experiments (B) and from 7 to 10 measurements from three independent experiments (C). *, P   <   0.05 
versus LPS plus dDAVP values and the other experimental conditions.     JEM VOL. 204, November 26, 2007 
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calyculin A (  Fig. 5 D  ). In sharp contrast,   cftr    −  /  −      CCDs were 
completely resistant to the eff  ect of dDAVP (  Fig. 5, D and E  ). 
In line with these fi  ndings, dDAVP signifi  cantly reduced 
the LPS-induced secretion of MIP-2 and TNF-     in   cftr  +/+     
but not in   cftr    −  /  −      CCDs (  Fig. 5 F  ). Moreover, calyculin A, 
okadaic acid, and CFTR  inh  -172 had no eff  ect on LPS-treated 
  cftr    −  /  −      CCDs (  Fig. 5 F  ). These findings indicate that the 
inhibitory activity of dDAVP requires functional CFTR to 
control the activity of the Ser/Thr protein phosphatases in 
renal collecting duct cells. 
  dDAVP inhibits UPEC-induced secretion of MIP-2 and TNF-     
in cultured CCDs 
  To study the dDAVP-mediated eff  ect on LPS-induced cell 
activation in a biologically relevant context, confl  uent cul-
tures of CCDs dissected from TLR4-defective C3H/HeJ mice 
and from TLR4-expressing C3H/HeN mice (hereafter referred 
to as   Lps  d     and   Lps  n     CCDs, respectively) were analyzed after 
exposure to UPECs (  6  ). dDAVP inhibited the secretion of 
MIP-2 and TNF-     in   Lps  n     CCDs after the addition of LPS or 
HT7 UPEC isolates (  Fig. 6, A and B  ).   In contrast, no detect-
able LPS or dDAVP-induced eff  ect was noted in   Lps  d     CCDs 
(  Fig. 6 A  ). In line with a previous study, which had demon-
strated that UPEC isolates also activate a TLR4-independent 
signaling pathway (  6  ), we found that incubating   Lps  d     CCDs 
with UPECs resulted in residual cell stimulation. However, 
the levels of MIP-2 and TNF-     secreted by   Lps  d     CCDs 
reached only      50% of those for   Lps  n     CCDs. Importantly, 
TLR4-independent cell activation was not aff  ected by preincu-
bating with dDAVP (  Fig. 6 B  ). These fi  ndings demonstrate that 
the suppressor eff  ect of dDAVP is limited to TLR4-mediated 
cell activation and suggest that it may well be of biological 
relevance during UPEC infection. 
  dDAVP-induced inhibition of the TLR4-mediated innate 
host defense in response to UPECs leads to exacerbated 
kidney infection in vivo 
  Increased AVP plasma levels are found in a variety of patho-
physiological situations associated with dehydration, such as 
severe renal infection or septic shock. The question arises 
of the extent that dDAVP infl  uences renal infl  ammatory 
  responses and bacterial clearance. To answer this question, 
either 1 ng/    l/h dDAVP or 1     l/h isotonic saline was ad-
ministered continuously to adult female   Lps  n     and   Lps  d     mice 
via an implanted osmotic pump while receiving normal water 
intake (see Materials and methods) (  48  ). Untreated   Lps  n     and 
  Lps  d     mice were kept in metabolic cages before and after the 
implantation of the osmotic pumps filled with dDAVP 
to fi  nd out whether dDAVP had similar antidiuretic ef-
fects in both mouse strains. dDAVP administration induced 
similar reduction in urine volume in both mouse strains 
(Table S1, available at http://www.jem.org/cgi/content/
full/jem.20071032/DC1). In accordance with these results, 
urine osmolality increased and plasma osmolality decreased in 
all HT7-infected mice treated with dDAVP but not in those 
given isotonic saline (Table S2). Moreover, the magnitude of 
CFTR  inh  -172 (see Materials and methods) was therefore also 
included in the analysis (  47  ). 10    −  4   M NPPB and Gly signifi  -
cantly impaired the inhibitory activity of dDAVP on LPS-
mediated secretions of MIP-2 and TNF-    , whereas 10    −  5   M 
amiloride, a potent inhibitor of ENaC, did not aff  ect cyto-
kine secretion (  Fig. 4 B  ). Importantly, 10    −  7   M CFTR  inh  -172 
also signifi  cantly diminished the inhibitory eff  ect of dDAVP 
on the LPS-mediated secretion of MIP-2 and TNF-     (  Fig. 
4 B  ). Similar to what has been reported for calyculin A and 
okadaic acid, 10    −  7   M CFTR  inh  -172 completely impaired the 
inhibitory eff  ect of 10    −  8   M dDAVP on the stimulation of the 
secretion of MIP-2 and TNF-     at all concentrations of LPS 
(1  –  1,000 ng/ml) tested (Fig. S3). 
  Confl  uent mpkCCD  cl4   cells exhibit a highly diff  erentiated, 
tight epithelial phenotype when grown on semipermeable 
fi  lters and develop high transepithelial electrical resistance 
(  >  1,500   Ω  .cm  2  ) (  21  ). The polarized (apical and/or basal) se-
cretion of MIP-2 was measured in the apical and basal me-
dium bathing confl  uent mpkCCD  cl4   cells grown on fi  lters 
after being exposed to 10 ng/ml LPS for 6 h. Apical addition 
of LPS resulted in an increase in predominantly apically di-
rected secretion of MIP-2 (  Fig. 4 C  ). In contrast, basal addi-
tion of LPS induced only a moderate increase in the secretion 
of MIP-2, which appeared to be predominantly basally di-
rected (  Fig. 4 C  ). These fi  ndings demonstrate the presence of 
a predominantly apically oriented mechanism of LPS recog-
nition and chemokine secretion in mpkCCD  cl4   cells. Simi-
larly, apical addition of 10    −  7   M CFTR  inh  -172 restored the 
LPS-stimulated apical and basal secretion of MIP-2 and TNF-     
after the apical or basal addition of LPS to confl  uent cultures 
of dDAVP-treated mpkCCD  cl4   cells grown on fi  lters (  Fig. 4 C  ). 
These fi  ndings indicate that the cAMP-regulated CFTR Cl    −    
channel, together with PP1 and PP2A, is involved in regulat-
ing the bipolarized cytokine secretion induced by LPS in renal 
collecting duct cells. 
  The inhibitory effect of dDAVP on LPS-stimulated cytokine 
secretion requires intact CFTR 
  To assess further the role of CFTR in the down-regulation of 
the LPS-induced infl  ammatory responses elicited by dDAVP, 
experiments were performed using primary cultures of CCDs 
dissected from   cftr  m1unc     and wild-type counterpart mice 
(hereafter referred to as   cftr  +/+     and   cftr    −  /  −      CCDs, respectively). 
Cultured   cftr  +/+     and   cftr    −  /  −      CCDs formed confl  uent layers of 
cuboid-shaped cells expressing K  8    –  K  18   cytokeratins and the 
tight junction  –  associated protein ZO-1 (  Fig. 5 A  ).   These cell 
layers were devoid of hematopoietic cells and did not express 
the bone marrow  –  derived cell marker CD45 (  Fig. 5 B  ).   cftr  +/+     
and   cftr    −  /  −      CCDs both expressed TLR4, whereas the ex-
pected size of CFTR transcripts was only observed in   cftr  +/+     
and not in   cftr    −  /  −      CCDs (  Fig. 5 C  ). dDAVP impaired the LPS-
induced activation of the phosphorylated NF-    B subunit 
p65/RelA in  cftr  +/+     CCDs ( Fig. 5, D and E ). As in mpkCCD  cl4   
cells, the decrease in phosphorylated p65 caused by dDAVP 
was no longer detected in LPS-treated wild-type   cftr  +/+     CCDs 
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inoculation of the HT7 isolates, the expression of proinfl  am-
matory mediators and the renal bacterial burden were ana-
lyzed. The levels of IL-1    , MIP-2, regulated on activation, 
changes in plasma and urinary osmolalities refl  ecting the 
hydroosmotic activity of dDAVP were very similar in the 
  Lps  n     and   Lps  d     mice (Table S2). 24 h after the transurethral 
  Figure 5.     The inhibitory effect of dDAVP on LPS-stimulated cytokine secretion requires functional CFTR. (A)   cftr  +/+    and   cftr   − / −     CCDs  formed 
confl  uent layers of cuboid cells and expressed cytokeratins 8  –  18 (red) and the tight junction  –  associated protein ZO-1 (green). Bars, 10     m. (B) CD45 
mRNA (405 bp) expressed in peritoneal macrophages was not detected in cultured   cftr  +/+    CCDs. (C) Cultured   cftr  +/+    CCDs and   cftr   − / −     CCDs expressed TLR4 
(311 bp) mRNAs. No amplifi  ed product of the expected size CFTR (636 bp) was detected in   cftr   − / −     CCDs. + represents reverse-transcribed RNA;   −   repre-
sents non  –  reverse-transcribed RNA. (D) Western blots analyses of phosphorylated (p-p65) and total (p65) NF-    B p65/RelA after incubation of   cftr  +/+    and 
  cftr   − / −     CCDs with or without LPS or LPS plus dDAVP, and with or without CFTR  inh  -172, okadaic acid, or calyculin A for 60 min (E). Error bars are the mean 
ratio values (arbitrary units)   ±   SE of densitometric analyses of phosphorylated over total p65 (  n   = 3) in the different conditions tested. (F) The secretion of 
MIP-2 was measured in   cftr  +/+    CCD and   cftr   − / −     CCD cell supernatants before and after adding LPS or LPS plus dDAVP with or without protein phosphatase 
and CFTR inhibitors for 6 h. Values are means   ±   SE from 7 to 11 wells from three to fi  ve separate experiments. *, P   <   0.05 versus LPS plus dDAVP values 
and the other experimental conditions.     JEM VOL. 204, November 26, 2007 
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infected mice 1d after bacterial challenge was signifi  cantly 
lower in dDAVP-treated   Lps  n     mouse kidneys than in the 
saline-infused   Lps  n     control mice (  Fig. 7, D and E  ). In sharp 
contrast, the number of PMNs in UPEC-infected   Lps  d     kid-
neys, which was signifi  cantly lower than that in infected   Lps  n     
mouse kidneys, was not aff  ected by the dDAVP treatment 
(  Fig. 7, D and E  ). The distribution of neutrophils in the py-
elic and inner medullary regions of infected kidneys appears 
to be rather variable (  Fig. 7 D  ). To confi  rm the immuno-
histological fi  ndings, neutrophil migration was also assessed 
by measuring myeloperoxydase (MPO) activity in renal homog-
enates (  51  ). MPO assay revealed that neutrophil migration 
was lower in   Lps  d     than in   Lps  n     kidneys colonized by HT7 
(  Fig. 7 F  ). dDAVP infusion induced a marked decrease in 
MPO activity in the kidneys from HT7-infected   Lps  n     mice 
as compared with that of saline-infused infected   Lps  n     mice 
but had no eff  ect on MPO activity in HT7-infected   Lps  d     
kidneys (  Fig. 7 F  ). These fi  ndings demonstrate that dDAVP 
also infl  uences infl  ammatory responses in vivo and suggest that 
dDAVP may be involved during bacterial kidney infection. 
They also raised the question as to whether in vivo blockade 
of the endogenous V2R, which is highly expressed in 
  collecting duct cells, could prevent the deleterious eff  ect of 
dDAVP on the infl  ammatory response and bacterial burden. 
To answer this question, C3H/HeN   Lps  n     mice subjected to 
water restriction were given intraperitoneal injections of 0.03 
or 0.3 mg/kg SR121463B 6 h before the transurethral in-
oculation of HT7. The mice received a second injection of 
SR121463B 14 h after bacterial infection. Administration of 
a low or high concentration of SR121463B alone had no 
eff  ect on the levels of mRNA expression of proinfl  amma-
tory mediators (  Fig. 8 A  ).   As a control, we checked that a 
high concentration (10    −  6   M) of SR121463B did not aff  ect 
the growth or viability of HT7   E. coli   isolates (unpublished 
data). Also, the administration of low doses of SR121463B 
did not signifi  cantly  aff   ect plasma and urine osmolality 
(Table S3, available at http://www.jem.org/cgi/content/full/
jem.20071032/DC1). Consistent with the decrease in urine 
osmolality caused by aquaresis (  31  ), a high dose of the V2R 
antagonist (0.3 mg/kg) signifi  cantly increased plasma osmo-
lality (Table S3). The administration of both low and high 
doses of SR121463B to infected mice resulted in signifi  cant 
dose-dependent increases in the expression of proinfl  amma-
tory mediators and in the production of MIP-2 and TNF-     
measured in whole kidney homogenates (  Fig. 8, A and B  ). 
Compared with untreated infected mice, SR121463B treated 
mice also displayed a signifi  cant dose-dependent decrease in 
the renal bacterial burden 24 h after challenge (  Fig. 8 C  ). 
Consistent with the stimulatory eff  ect of the V2R antagonist 
on proinfl  ammatory mediators, the number of CFU detected 
in kidneys proportionally decrease as a function of the dose of 
SR121463B administered (  Fig. 8 C  ), whereas the number of 
Ly6-G  –  positive neutrophils infi  ltrating the kidneys and the 
levels of MPO activity remained almost the same in infected 
mice receiving a low dose (0.03 mg/kg) of SR121463B, and 
then fell signifi  cantly in infected mice treated with the high 
normal T cell expressed and secreted (RANTES), MCP-1, 
and TNF-     expression were lower in the dDAVP-treated 
  Lps  n     mice than in mice infused with isotonic saline after bac-
terial infection (  Fig. 7 A  ).   UPEC infection induced only a 
moderate increase in proinfl  ammatory mediator expression 
in the kidneys of   Lps  d     mice, which was not altered by the 
dDAVP treatment (  Fig. 7 A  ). dDAVP also dampened the 
production of MIP-2 and TNF-     measured in whole-cell 
homogenates from HT7-infected   Lps  n     mice but had no eff  ect 
on the production of MIP-2 and TNF-     by HT7-infected 
kidneys of   Lps  d     mice (  Fig. 7 B  ). These data are in accordance 
with the in vitro observations and further confi  rm that the 
suppressor eff  ect of dDAVP is restricted to TLR4-dependent 
immune activation. The importance of TLR4 activation 
during UPEC infection was demonstrated by the fi  nding that 
the renal bacterial burden was markedly greater in   Lps  d     than 
in   Lps  n     wild-type mice. Importantly,   Lps  n     mice treated with 
dDAVP were signifi  cantly more susceptible to UPEC infec-
tion than their   Lps  n     counterparts receiving isotonic saline, with 
a 20-fold greater bacterial CFU 1d after infection (  Fig. 7 C  ). 
In contrast, dDAVP had no eff  ect on the renal bacterial counts 
in   Lps  d     mice (  Fig. 7 C  ). 
  Chemoattractant chemokines, such as MIP-2, play a 
key role in the migration of PMNs to mucosal sites of in-
fl  ammation to produce effi   cient bacterial clearance (  49, 50  ). 
In accordance with the lower expression of chemokines in 
infected   Lps  n     mouse kidneys treated with dDAVP, the num-
ber of Ly6-G  –  positive PMNs found on kidney sections from 
  Figure 6.     Differential action of dDAVP on LPS- and UPEC-stimulated 
cytokine secretion in   Lps  n     and   Lps  d    CCD cells. Secretion of MIP-2 and 
TNF-     was measured in confl  uent cultures of   Lps  n    and   Lps  d    CCDs  incu-
bated with LPS alone or LPS plus dDAVP for 6 h (A), or incubated with  
E. coli   HT7 isolates (5   ×   10  5   bacteria per well) alone or HT7 plus dDAVP for 
3 h (B). Values are means   ±   SE from fi  ve to seven separate wells from three 
separate experiments under each condition tested. *, P   <   0.05 versus LPS or 
HT7 values (open bars) or HT7 and HT7 plus dDAVP values (shaded bars).     2846 ARGININE VASOPRESSIN LIMITS RENAL INFLAMMATION | Chassin et al.
rapid renal clearance of bacteria by stimulating proinfl  amma-
tory mediators. The benefi  cial eff  ect of the V2R antagonist 
appeared to be restricted to the kidney, because the number 
of CFUs detected in the bladder did not considerably diff  er 
in untreated and SR121463B-treated mice (unpublished 
data). These fi  ndings support the idea that this potent V2R 
blocker agent, which may impair the retrograde ascent of 
UPECs via its aquaretic eff  ects (  31  ), eff  ectively antagonizes 
the action of endogenous dDAVP, leading to a signifi  cant 
dose (0.3 mg/kg) of SR121463B (  Fig. 8, D  –  F  ). Only a few 
UPECs (    3,000 CFU per kidney) and infi  ltrating neutrophils 
were detected in kidneys from 0.3 mg/kg SR121463B  –
  injected mice (  Fig. 8, E and F  ). Furthermore, the small num-
ber of infi  ltrating neutrophils present in the infected kidneys 
from the 0.3 mg/kg SR121463B  –  injected mice was very 
similar to that found in dDAVP-treated   Lps  n     mice, which 
exhibited      110-fold more bacteria in their kidneys (  Fig. 7 D  ). 
These results suggest that SR121463B administration promoted 
  Figure 7.     Inhibitory action of dDAVP on infl  ammatory response, bacterial colonization, and neutrophil infi  ltrates in kidneys of mice chal-
lenged with UPECs. dDAVP or isotonic saline was delivered via osmotic minipumps to   Lps  n    and   Lps  d    mice. Expression of proinfl  ammatory mediators, 
production of cytokines, bacterial counts, numbers of infi  ltrating neutrophils, and MPO activity were determined in kidneys from isotonic saline control 
(  −  dDAVP) and dDAVP-treated (+dDAVP)   Lps  n    (open bars) and   Lps  d    (shaded bars) mice 24 h after the transurethral inoculation of HT7 isolates. (A) Relative 
fold increase of each mRNA level compared with that measured in naive mice. (B and C) Production of MIP-2 and TNF-     (B) and bacterial counts (C) in 
kidneys from HT7-infected   Lps  n    and   Lps  d    mice. (D and E) Illustrations (D) and quantifi  cation (E) of infi  ltrating Ly6-G  –  positive neutrophils (arrowheads) in 
kidney sections from HT7-infected   Lps  n    and   Lps  d    mice pretreated without (  −  dDAVP) or with dDAVP (+dDAVP). Bars, 50     m. (F) Levels of MPO activity 
measured in kidney homogenates from uninfected and HT7-infected   Lps  n    and   Lps  d    kidneys treated or not with dDAVP. All values are means   ±   SE from 
measurements performed on six to eight different kidneys in each group tested. *, P   <   0.05 between groups.     JEM VOL. 204, November 26, 2007 
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      DISCUSSION   
    Renal tubule collecting duct cells play an active role in initiating 
the infl  ammatory host defense during renal bacterial infection 
(  6  ). In this paper, we show that the antidiuretic peptide AVP, 
(P < 0.05) increase in the expression of proinfl  ammatory 
mediators and the subsequent activation of PMN infl  ux, thereby 
promoting the recruitment of neutrophils to kill bacteria in-
vading kidneys. 
  Figure 8.     The V2R antagonist SR121463B stimulates infl  ammatory response and promotes bacterial clearance in the kidneys of mice 
challenged with UPECs.   Lps  n    mice received intraperitoneal injections of SR121463B (0.03 or 0.3 mg/kg in 100     l) 6 h before and after the transurethral 
inoculation of HT7 isolates. The expression of proinfl  ammatory mediators, bacterial counts, numbers of infi  ltrating neutrophils, and MPO activity were 
performed 24 h after the transurethral inoculation of HT7 isolates. (A  –  C) Relative fold increase of each mRNA level of proinfl  ammatory mediator com-
pared with that measured in naive mice (A), production of MIP-2 and TNF-     (B), and bacterial counts (C) in kidneys from untreated and SR121463B-
treated   Lps  n    mice challenged with HT7. (D) Illustrations of neutrophil infi  ltrates (brown) in untreated (top), and 0.3 mg/kg SR121463B  –  treated (bottom) 
  Lps  n    mice challenged with HT7. Bars, 50     m. (E and F) Quantifi  cation of infi  ltrating neutrophils (E) and MPO activity (F) in kidneys from HT7-infected   Lps  n   
mice pretreated or not with SR121463B. All values are means   ±   SE from measurements performed on six to eight different kidneys in each group tested. 
*, P   <   0.05 versus HT7 values and between groups.     2848 ARGININE VASOPRESSIN LIMITS RENAL INFLAMMATION | Chassin et al.
tional interaction between CFTR and PP2A. Using mass 
spectrometry, Thelin et al. (  43  ) demonstrated that the PP2A 
catalytic A regulatory (A    ) and B         (B        ) regulatory subunits 
associate with CFTR, and that the latter binds directly to the 
C terminus of the CFTR molecule. PP2A inhibitors have 
also been shown to increase cAMP-stimulated CFTR currents 
in excised patches of airway epithelia and in intact mouse 
jejunum, and to delay their deactivation in colonic carcinoma 
Caco-2 cells (  43, 44  ), which is consistent with physical inter-
action between CFTR and PP2A. Although neither calyculin 
A nor okadaic acid had any effect on dDAVP-stimulated 
CFTR-mediated Cl    −    secretion, they both impaired the in-
hibitory eff  ect of dDAVP on p65/RelA phosphorylation and 
on the secretion of MIP-2 and TNF-     elicited by LPS in 
mpkCCD  cl4   cells. CFTR blocking agents also impaired the 
inhibitory action of dDAVP on LPS-mediated activation. 
Collectively, these fi  ndings suggest that the closely associated 
CFTR and PP2A proteins are key signaling molecules activated 
by dDAVP, and that they down-regulate LPS-stimulated, 
TLR4-mediated infl  ammatory responses in renal collecting 
duct cells. 
  The cAMP-regulated CFTR is associated with infl  am-
matory processes in other cell types. For example, defective 
CFTR function is responsible for cystic fi  brosis, a chronic 
infl  ammatory lung disease characterized by bacterial coloni-
zation of the respiratory mucosa and an exaggerated and 
destructive chronic infl  ammatory response (  59  ). CFTR has 
been shown to regulate the expression of RANTES, IL-8, 
IL-10, and inducible nitric oxide synthase (  60  ). Interestingly, 
Estell et al. (  60  ) also demonstrated that the CFTR-mediated 
NF-    B activation and RANTES expression require the 
insertion of CFTR into the plasma membrane. In this study, 
we show that the activation of the cAMP  –  PKA pathway by 
dDAVP, which down-regulates LPS-induced infl  ammatory 
responses in renal collecting duct cells, also requires an intact 
CFTR, which is inserted into the apical membrane of col-
lecting duct cells in response to cAMP stimulation (  12, 13  ). 
The inhibitory action of dDAVP seems to be restricted to the 
TLR4-mediated signaling pathway, because administration 
of the peptide hormone to mice infected by UPECs only 
altered infl  ammatory responses mediated by the TLR4 sig-
naling cascade and not pathways independent of TLR4 (  6  ). 
Our fi  ndings also suggest that activation of the PP2A  –  CFTR 
complex by dDAVP involves a dephosphorylation process on 
the TLR4-mediated, NF-    B signaling pathway. This sce-
nario is consistent with a previous report showing that NF-
    B activation and increased IL-8 production in cystic fi  brosis 
tracheal epithelial cells is abrogated when dominant-negative 
signaling molecules, such as MyD88, are expressed (  61  ). 
  Under conditions of dehydration, a rise in the circulatory 
level of vasopressin will stimulate NaCl and water reabsorp-
tion from the terminal parts of the nephron. We show that 
AVP, via its stimulatory eff  ect on CFTR and PP2A, simulta-
neously reduces host infl  ammatory responses and favors renal 
bacterial invasion. This was illustrated by the fact that chronic 
administration of dDAVP reduces the renal expression of 
which acts on collecting duct cells, is also a potent immuno-
modulator of the innate response elicited by UPECs. Previous 
studies have demonstrated that the stimulation of proinfl  am-
matory responses in a variety of cell types is associated with 
down-regulation of cAMP and increased expression of intra-
cellular adhesion molecule (ICAM) 1 (CD54) and vascular 
cell adhesion molecule 1, which are involved in the cell-to-cell 
contact-mediated host response (  17, 52  ). In contrast, activa-
tion of cAMP-mediated signaling may suppress the immune 
response elicited by LPS and TNF-    . Agents that increase 
cellular cAMP have also been shown to inhibit the TNF-
induced expression of ICAM-1 and vascular cell adhesion 
molecule 1 in human lung epithelial A549 cells (  52  ), airway 
smooth muscle cells (  17  ), and activated macrophages (  18, 19  ). 
In this study, dDAVP also inhibited the LPS-induced expres-
sion of ICAM in mpkCCD  cl4   cells (unpublished data). A rise in 
cellular cAMP content was also shown to induce selective 
suppression of the activation of NF-    B in splenic B lympho-
cytes by blocking the phosphorylation of NF-    B/RelA and 
the degradation of I    B-     (  53  ). Similar to these previous fi  ndings, 
we show here that dDAVP inhibited both the LPS-induced 
degradation of I    B-     and its stimulation of phosphorylated 
p65/RelA, as well as LPS-mediated NF-    B activation and 
cytokine secretion in mpkCCD  cl4   cells. Ser/Thr protein 
phosphatases play key roles in the regulation of phosphoryl-
ation of the NF-    B transcription factors. The SV40 small 
antigen, which associates with PP2A and inhibits its activity, 
enhances the activity of NF-    B (  54  ). PP2A has been shown to 
dephosphorylate RelA directly in melanoma cell lines (  55  ). 
In addition, the inhibition of PP1 and PP2A by okadaic acid 
induces the nuclear translocation and activation of NF-    B, 
as well as its activation in Jurkat cells and human neutro-
phils (  56, 57  ). We show that after specifi  c binding to V2R, 
dDAVP stimulates PP2A activity in both untreated and LPS-
treated mpkCCD  cl4   cells. These fi  ndings are consistent with 
those of a previous immunohistochemical study demon-
strating that the expression of the PP2A protein is restricted 
to the epithelial cells of the distal nephron of adult rat and 
mouse kidneys (  33, 34  ). We show that inhibition of PP2A 
activity by exposure to low concentrations of okadaic acid and 
calyculin A blunted the inhibitory eff  ect of dDAVP on the 
LPS-stimulated secretion of MIP-2 and TNF. This suggests 
that the cAMP-dependent PKA activation caused by dDAVP 
leads to increased PP2A activity, which in turn inhibits I    B-     
degradation and p65/RelA phosphorylation in renal collecting 
duct epithelial cells. 
  We also demonstrate that the inhibitory action of dDAVP 
on cellular activation requires an intact CFTR. The regula-
tion of CFTR by PKA has been extensively studied. The 
regulatory domain (R domain) of CFTR harbors multiple 
consensus sites for phosphorylation by PKA. The phosphory-
lation of the R domain regulates the opening of the CFTR 
channel (  58  ). Multiple phosphatases may deactivate CFTR 
(  38  –  41  ). PP2A has been shown to be one of the most potent 
protein phosphatases involved in the dephosphorylation of 
purifi  ed CFTR. Vastiau et al. (  42  ) reported a direct and func-JEM VOL. 204, November 26, 2007 
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Cl    −    channel activity. Importantly, the negative regulatory 
action of dDAVP described targets the site to which ascend-
ing uropathogenic   E. coli   preferentially adheres in vivo, and 
may therefore produce an important downstream eff  ect on 
host defense activation, bacterial proliferation, and disease 
progression. Identifi  cation of this novel negative regulatory 
mechanism illustrates the important infl  uence of hormonal 
control on local innate immune recognition and identifi  es a 
previously unrecognized factor of disease susceptibility and 
clinical outcome. 
  MATERIALS AND METHODS 
  Inhibitors.       NPPB was obtained from Research Biochemicals International. 
The thiazolidinone CFTR inhibitor 3-[(3-trifl  uoromethyl)phenyl]-5-[(4-
carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone (CFTR  inh  -172) was pro-
vided by A.S. Verkman (University of California, San Francisco, San Francisco, 
CA). The V2R antagonist SR121463B (1-[4(N-tert-butylcarbamoyl)-2-
methoxybenzene sulfonyl]-5-ethoxy-3-spiro-[4-(2-morpholinoethoxy)
cyclohexane]indol-2-one, phosphate monohydrate) was provided by C. Serradeil-
Le Gal (Sanofi  -Aventis, Toulouse, France). SR121463B was dissolved in 
10    −  2   M DMSO and then in 0.9% NaCl to produce the appropriate fi  nal 
concentration. PKA (H89) and PKC (GF109203X) inhibitors were obtained 
from Merck Biosciences. All reagents used were tested for the absence of LPS 
contamination using the   Limulus   amebocyte lysate assay (BioWhittaker). 
    Mice, bacteria, and retrograde infection studies.       Adult female C3H/
HeN (  Lps  n    ) and C3H/HeJ (  Lps  d    ) mice were obtained from the Jackson Lab-
oratory. Homozygous mutant   cftr  m1unc     (  cftr    −  /  −     ) mice were obtained by a tar-
geted mutation of the   cftr   gene (  23  ), and their wild-type counterpart (  cftr  +/+    ) 
mice were obtained from the Centre de D  é  veloppement des Techniques 
Avanc  é  es pour l  ’  Exp  é  rimentation Animale (provided by M.F. Bertrand, 
Centre National de la Recherche Scientifi  que, Orl  é  ans, France). Mice origi-
nally derived from ES129/Sv cells injected into C57BL/6J mice embryos 
have been further backcrossed on a C57BL/6J background for three genera-
tions and were then intercrossed. All mice were housed under specifi  c 
pathogen-free conditions and used when 8  –  13 wk of age. Renal retrograde 
UTI was performed on   Lps  n     and   Lps  d     mice, as previously described (  6  ), using 
UPEC strain HT7. This UPEC strain was isolated from the urine of a 
woman with acute pyelonephritis and expresses the   pap   adhesin-encoding 
genes but lacks the   hly       -hemolysin  –  encoding gene. The experimental pro-
cedures for the continuous infusion of dDAVP and administration of the 
V2R antagonist SR121463B before bacterial retrograde infection are listed 
in Supplemental materials and methods (available at http://www.jem.org/
cgi/content/full/jem.20071032/DC1). The experiments were performed 
in accordance with the guidelines of the French Agricultural Offi   ce and in 
compliance with the legislation governing animal studies. 
    Cell culture.       Experiments were performed on mpkCCD  cl4   cells (  21  ) seeded 
on glass coverslips, Petri dishes, or Transwell permeable fi  lters (0.4-    m pore 
size, 1-cm  2   insert growth area; Corning Costar Corp.) and on primary cul-
tures of isolated CCDs microdissected from the kidneys of   Lps  n     and   Lps  d     
mice, or from the kidneys of   cftr    −  /  −      and   cftr  +/+     mice, as previously described 
(  6, 21  ). Cells were grown in a modifi  ed defi  ned medium (DMEM/Ham  ’  s 
F12; 1:1 vol/vol; Invitrogen) supplemented with hormones and 2% fetal calf 
serum (  21  ) in a 5% CO  2  -95% air atmosphere. Confl  uent cells were incu-
bated with purifi  ed   E. coli   (0111:B4 LPS Ultra-Pure; InvivoGen) or HT7 (5   ×   
10  5   bacteria per well). 
    Transient transfection and luciferase reporter assay.       15   ×   10  6   mp-
kCCD  cl4   cells per milliliter were transfected by electroporation with the 
p(    B)  3   IFN-Luc plasmid (a Luciferase cis-reporter system containing 7  ×   AP-1 
and 3  ×   NF-    B enhancer elements), as previously described (  69  ). Luciferase 
activity was measured with a luminometer using the Luciferase Assay System 
(Promega) according to the manufacturer  ’  s instructions. 
proinfl  ammatory mediators and the recruitment of PMNs, and 
increased the susceptibility of   Lps  n     (but not   Lps  d    ) mice to 
UPEC infection. The reduction in urine fl  ow resulting from 
increased NaCl and water reabsorption may also contribute 
to the increased susceptibility to ascending bacterial infection. 
However, there is no reason why this eff  ect should be restricted 
to   Lps  n     mice. 
  It is generally agreed that adequate hydration helps to 
improve the resolution of UTIs and even to prevent them, 
although there is no direct clinical evidence that dehydration 
promotes UTIs in humans (  62  ). However, previous experi-
mental studies have demonstrated that water deprivation does 
considerably increase the risk of   E. coli    –  induced pyelonephritis 
in rats (  63  ) and that enterococcal-induced pyelonephritis in 
rats could be cured by sustained water diuresis (  64  ). These stud-
ies are in accordance with the present fi  ndings showing that 
vasopressin impairs immune response both in vivo and in vitro. 
This means that it is conceivable that a sustained increased in the 
concentration of vasopressin in kidneys would tend to inhibit 
the local immune response and favor the bacterial colonization 
by ascending uropathogens. Such situations could account, at 
least in part, for the high frequency of UTI in elderly patients, 
who are particularly susceptible to dehydration. 
  The action of dDAVP in the down-regulation of infl  am-
matory response observed in UPEC-infected kidneys has 
been confi  rmed by the blocking experiments using a V2R 
antagonist. Previous binding studies have demonstrated that 
nonpeptide V2R antagonists, including salts of SR121463 
and Tolvaptan, display high competitive affi   nity for the renal 
V2R from diff  erent species, including mice and humans 
(  31, 65, 66  ). These very selective compounds also display only 
very low affi   nity for other AVP receptor subtypes and do not 
bind to many of the receptors that are unrelated to AVP (  65, 66  ). 
In in vivo studies, these V2R antagonists induce marked 
aquaresis in healthy and diseased animals, and clinical trials 
have shown that they improve hyponatremia, congestive 
heart failure, and various other diseases associated with volume 
overload (  31, 66  –  68  ). Oral or intravenous administration of 
SR121463 salts induce dose-dependent aquaresis lasting 2  –  6 h 
(  65  ). Unlike conventional diuretics, such as furosemide, the 
action of the SR121463 salts is purely aquaretic, with no ma-
jor changes in urinary Na  +   or K  +   excretion (  31  ). We show 
that blockade of V2Rs by SR121463B stimulated the expres-
sion of proinfl  ammatory mediators in the kidneys of infected 
mice. Furthermore, the combination of the stimulated ex-
pression of proinfl  ammatory mediators and aquaresis caused 
by high doses of SR121463B (0.3 mg/kg) resulted in the vir-
tually complete clearance of UPECs colonizing the kidneys. 
These fi  ndings strongly suggest that in vivo, as in cultured 
collecting duct cells, dDAVP has a potent inhibitory eff  ect on 
the infl  ammatory response in UPEC-infected kidneys. 
  To conclude, this study demonstrates that dDAVP, in 
addition to its key role in fl  uid homeostasis, also infl  uences 
local innate immune recognition in the kidney by inhibiting 
TLR4-mediated cell activation in collecting duct epithelial 
cells. This pathway involves both PP2A and intact CFTR 2850 ARGININE VASOPRESSIN LIMITS RENAL INFLAMMATION | Chassin et al.
    Cellular cAMP assay.       Confl  uent mpkCCD  cl4   cells were incubated with 
dDAVP, or with LPS or LPS plus dDAVP for 6 h. The cAMP content was 
measured using the cAMP Biotrak EIA system (GE Healthcare), according 
to the manufacturer  ’  s instructions. 
    Statistics.       Results are expressed as means   ±   SE. Signifi  cant diff  erences were 
analyzed using the unpaired Student  ’  s   t   test and by analysis of variance using 
the Student-Newman-Keuls test and the Bonferroni   t   test for multiple com-
parison procedures. P   <   0.05 was considered signifi  cant. 
    Online supplemental material.       Fig. S1 depicts the expression of TLR4 
and associated signaling molecules in confl  uent mpkCCD  cl4   cells. Fig. S2 
provides an illustration of mpkCCD  cl4   cells forming domes and the mRNA 
expression of TLR4 and associated signaling molecules. Fig. S3 illustrates the 
antagonist eff  ect of Ser/Thr protein phosphatases and CFTR on the inhibi-
tory action of dDAVP on LPS-mediated cytokine secretion. Table S1 sum-
marizes the eff  ects of dDAVP infusion on the volume of urine excreted by 
  Lps  n     and   Lps  d     mice housed in metabolic cages. Tables S2 and S3 show blood 
and urinary osmolality values 24 h after the inoculation of UPECs to un-
treated and dDAVP-treated mice or SR121463B-treated mice, respectively. 
Supplemental materials and methods provides information about the condi-
tions of retrograde infection studies, dDAVP infusion, urine collection of 
mice acclimatized to metabolic cages, and administration of the V2R antag-
onist and TLR4 siRNA studies. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20071032/DC1. 
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